Record 29 policymakers to address 2008 TOPRA Symposium

This year’s TOPRA Symposium has a record number of participants from EMEA, the European Commission and National Agencies. These 29 individuals will join their esteemed industry counterparts to deliver an unparalleled regulatory affairs programme. As scientists, regulators and former practitioners from across the pharmaceutical, medical technologies, and veterinary disciplines, these key policymakers from across the European Medicines Regulatory Network hold valuable insights for industry and peers. They will be joined by a number of exceptional field of industry panellists and other leading experts.

Agency Representatives, European Commission and EMEA staff presenting and discussing topics at the Symposium include:

  • János Borvendeg - Hungarian Institute of Pharmacy and CHMP member
  • Patrick Dehaumont - Co-chair of Heads of Medicines Agency (HMA) Benchmarking Working group and Head of The French National Agency for Veterinary Medicinal Products Agence Nationale du Médicament Vétérinaire, ANMV, France
  • Christophe Debruyne - Federal Agency for Medicines and Health Products, Belgium
  • Gabriele Eibenstein - Head of Unit Regulatory Affairs, BfArM, Germany
  • Stefan Fuehring - Unit F2 Pharmaceuticals, European Commission
  • Kornelia Grein - Head of Sector, Safety of Veterinary Medicines, EMEA
  • Thomas Heynisch - Unit F5: Competitiveness in the Pharmaceuticals Industry and Biotechnology, European Commission
  • Peter Karolyi - EMEA
  • Gábor Kulcsár - Director, Directorate of Veterinary Medicinal Products, Hungary
  • Melanie Leivers - Deputy Head of Sector, Veterinary Marketing Authorisation Procedures, EMEA
  • Xavier Luria Oller - Head of Sector, Safety and Efficacy of Medicines, EMEA
  • David Mackay - Head of Veterinary Medicines and Inspections, EMEA
  • Sarah Morgan - Group Manager - Pharmacovigilance Risk Management, MHRA, UK
  • Ann O’Connor - Head of Medical Devices Section Irish Medicines Board, Eire
  • Tamas Paal - Professor of Regulatory Affairs and President, Operative Board of National Institute of Pharmacy, Hungary
  • Kristin Raudsepp - Director General, Ravimiamet, Estonia
  • Agnes Saint Raymond - Head of Sector Scientific Advice and Orphan Drugs - EMEA
  • Francisco Javier Reviriego Gordejo - Head of Sector Disease Control and Identification, DGSanCo
  • Norman R. Schmuff - Branch Chief, Division of Pre-Marketing Assessment II Office of New Drug Quality Assessment Center for Drug Evaluation and Research U.S. Food and Drug Administration, FDA, USA
  • Matthias Sennwitz - EMEA
  • Ondřej Slanař - SUKL, Czech Republic
  • Zsuzsanna Szepezdi - Director General, National Institute of Pharmacy, Hungary
  • Martin Terberger - Head of Unit F2 Pharmaceuticals, European Commission
  • Anne Tobin - Irish Medicines Board, Eire
  • Jean-Hugues Trouvin - Chairman of the EMEA Biotechnology Working Party (BWP), Afssaps, France
  • Daniela Vasilescu - Head of the Bureau for Management of European Procedures, National Medicines Agency, Romania
  • Martina Weise - BfArM and Vice Chair EMEA Biosimilars working party, Germany
  • Esther Werner - Chair, CMD(v) and Head of Section - Bacterial Vaccines and Immune Sera, Department: Department of Veterinary Medicine, Germany
  • Gergely Zajzon - Head of Development and Database Department, National Institute of Pharmacy (OGYI), Hungary